Teva uses the agilent trs100 to achieve regulatory milestone for content uniformity testing with the fda

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) announced today that the fda has approved a content uniformity (cu) method using the agilent trs100 raman quantitative pharmaceutical analysis system. the submitting company, teva pharmaceutical industries ltd., is an agilent raman spectroscopy customer and global leader in generic and biopharmaceuticals. in 2021, the u.s. food and drug administration (fda) approved the company's cu method application, which was developed
A Ratings Summary
A Quant Ranking